Neurocrine Biosciences | NBIX - Чистый доход





Чистый доход Изменить Дата
AbbVie USD 695M 1.12B 2026-03
Acadia Pharmaceuticals USD 3.64M 269.93M 2026-03
Agios Pharmaceuticals USD -99.11M 8.93M 2026-03
ALKERMES USD -66.48M 115.82M 2026-03
Alnylam Pharmaceuticals USD 205.99M 19.57M 2026-03
Amgen USD 1.82B 486M 2026-03
Biogen USD 319.5M 368.4M 2026-03
BioMarin Pharmaceutical USD 105.53M 152.1M 2026-03
Cytokinetics USD -206.03M 23M 2026-03
Enanta Pharmaceuticals USD -22.29M 93.76M 2024-12
Exelixis USD 210.47M 34.06M 2026-03
Gilead Sciences USD 2.02B 162M 2026-03
Halozyme Therapeutics USD 150.05M 291.64M 2026-03
Incyte USD 303.33M 4.05M 2026-03
Ionis Pharmaceuticals USD -93M 136M 2026-03
Nektar Therapeutics USD -36.08M 978K 2025-12
Neurocrine Biosciences USD 197.9M 44.2M 2026-03
Pfizer USD 2.69B 4.34B 2026-03
Prothena USD 32.72M 54.31M 2026-03
Regeneron Pharmaceuticals USD 727.2M 117.4M 2026-03
Repligen USD 8.33M 4.95M 2026-03
Rigel Pharmaceuticals USD 12.42M 13.45M 2024-09
Sarepta Therapeutics USD 330.96M 743.18M 2026-03
Teva Pharmaceutical Industries USD 369M 111M 2026-03
Ultragenyx Pharmaceutical USD -185M 56M 2026-03
Vertex Pharmaceuticals USD 1.03B 159.7M 2026-03
Xoma USD -17.24M 33.23M 2024-09